Randomized phase II neoadjuvant study (GepartNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC)
Loibl, S., et al. Randomized phase II neoadjuvant study (GepartNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). Clinical Science Symposium Presented at: American Society of Clinical Oncology (ASCO); 2018 June 2, Chicago, IL.